tetraethylammonium
Small moleculeexperimental
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. Tetraethylammonium blocks of apamin-sensitive and insensitive Ca2(+)-activated K+ channels. It is a weak agonist of the nicotinic receptor. Tetraethylammonium produces transient reductions in blood pressure. Tetraethylammonium hydroxide is used as a soluble source of hydroxide ions and in the synthesis of ionic organic compounds. — NCATS
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2002 (NCT00166166)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC[N+](CC)(CC)CC- Mol. weight
- 130.2511 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTetraethylammonium ↗
- NCATS5AV7G7EIEE ↗
Also known as
- tetraethylammonium
- tetraethylammonium
- tetraethylammonium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00185003 | Phase 1 | Jan 1, 2003 | Radboud University, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT00166166 | Phase 2 | Jul 1, 2002 | Emory University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| ZonMw: The Netherlands Organisation for Health Research and Development | Academic/Hospital | 1 | 0 | 1 | 2003 |
3 organizations
Page 1 / 1